Longevity Bros
Home › Glossary › Lp(a)
Glossary

Lp(a): the inherited lipid risk factor you only need to test once

One in five people carries a high Lp(a) and most of them do not know, because it is not on a standard lipid panel and lifestyle does not move it. It is the single most useful once-in-a-lifetime test.

Reviewed by the Longevity Bros team · Updated 1 October 2026

Before you read onResearch and educational information for adults, not medical advice. This entry explains one longevity term — what it means, why it matters and what the evidence says — and nothing here diagnoses, treats, cures or prevents any condition. Baseline labs come before anything, and your own physician has the final word. Longevity Bros offers coaching and written research protocols only — we do not sell, supply, source or ship any compound.

What it means

Lipoprotein(a) is an LDL particle with an extra protein, apolipoprotein(a), bolted on. The apo(a) protein resembles plasminogen, so Lp(a) is both atherogenic (it carries ApoB and cholesterol into the artery wall) and pro-thrombotic and pro-inflammatory. Its level is more than 90% genetic, set by the LPA gene, and stable across life.

About 20% of people have levels above 50 mg/dL (roughly 125 nmol/L), the threshold at which risk rises clearly.

Why it matters for longevity

High Lp(a) roughly doubles heart-attack risk and is the main cause of calcific aortic stenosis — independently of LDL cholesterol. Because it is inherited, it explains many of the heart attacks in fit, lean people with "good cholesterol" and a family history. Knowing it changes how aggressively everything else should be managed.

What the evidence says

Mendelian randomisation and large cohorts (Copenhagen General Population Study, UK Biobank) show a continuous, causal relationship between Lp(a) and coronary disease, stroke and aortic stenosis. The 2022 European Atherosclerosis Society consensus recommends every adult be tested at least once.

Statins do not lower Lp(a) (they may raise it slightly); PCSK9 inhibitors lower it by 20–25%; niacin lowers it but without outcome benefit. Dedicated drugs — the antisense oligonucleotide pelacarsen and the siRNAs olpasiran and lepodisiran — lower it by 80–95%, and the first outcome trial (HORIZON) is expected to report in 2025–2026.

How to measure or use it

Related

Frequently asked questions

Can I lower Lp(a) with diet or exercise?

Barely. It is more than 90% genetic. Lifestyle lowers the other risk factors, which is the current strategy.

How often should I test it?

Once. It is stable across life unless a drug that affects it is started.

What drugs lower Lp(a)?

PCSK9 inhibitors by 20–25%; the new antisense and siRNA drugs by 80–95%, with outcome trials reporting from 2025.

Your own protocol

Want this applied to your own numbers?

Fifteen minutes of intake, your labs, a human-reviewed protocol within about 24 hours, three documents, a free coach call and check-ins through the cycle. €399, follow-up included.

Build my protocol Book a 15-minute call